Melanoma cells depend on sustained proteasomal function for survival. However, bortezomib, the first proteasome inhibitor in clinical use, is not sufficient to improve the poor prognosis of metastatic melanoma patients. Since the proteasome is also expressed in all normal cell compartments, it is unclear how to enhance the efficacy of bortezomib without exacerbating secondary toxicities. Here, we present pharmacological and genetic analyses of mechanisms of resistance to proteasome inhibition. We focused on Bcl-2, Bcl-x L and Mcl-1 as main antiapoptotic factors associated with melanoma progression. Despite an efficient blockage of the proteasome, bortezomib could not counteract the intrinsically high levels of Bcl-2 and Bcl-x L in melanoma cells. Moreover, Mcl-1 was only downregulated at late time points after treatment. Based on these results, a combination treatment including (À)-gossypol, an inhibitor of Mcl-1/Bcl-2/Bcl-x L , was designed and proven effective in vivo. Using a specific RNA interference approach, the survival of bortezomib-treated melanoma cells was found to rely primarily on Mcl-1, and to a lesser extent on Bcl-x L (but not on Bcl-2). Importantly, neither Mcl-1 nor Bcl-x L inactivation affected the viability of normal melanocytes. This hierarchical requirement of Bcl-2 family members for the maintenance of normal and malignant cells offers a therapeutic window to overcome melanoma chemoresistance in a tumor cell-selective manner.
Metastatic melanoma remains a daunting clinical problem. In addition to a continuous rise in incidence, the prognosis of patients at late stages of the disease has not significantly improved in the last three decades. 1 However, recent discoveries elucidating aspects of the underlying molecular biology of metastatic melanoma have led to optimism about the rational design of more effective treatments. 2, 3 The proteasome may one such attractive new target for cancer therapeutics. In experimental models, melanoma cells are highly dependent on proteasomal function for survival. [4] [5] [6] [7] [8] Thus, bortezomib, the prototype of selective proteasome inhibitors currently in clinical trials, 9 can compromise the viability of a spectrum of melanoma cells derived from early, intermediate or late stages of the disease. 6 Genetic and functional studies in melanoma and other cancers have identified the proapoptotic protein NOXA as an early target of bortezomib. [5] [6] [7] [8] 10, 11 The specific contribution of NOXA to cell death may be context dependent, 12 but a main role of this protein is to neutralize the antiapoptotic factor Mcl-1. 13, 14 Intriguingly, while a 5-to 20-fold accumulation of NOXA in melanoma cells can be visualized as early as 6 h posttreatment with bortezomib, caspase activation may not be detected until 12-48 h later. 6 Therefore, these cells seemingly retain antiapoptotic activities to counteract proteasome inhibition and NOXA upregulation. Understanding how normal and tumor cells activate survival pathways to compensate for proteasomal inhibition may be important in vivo. For example, although bortezomib can synergize with various chemotherapeutic agents, this proteasome inhibitor failed to reveal significant efficacy in a recent clinical trial with metastatic melanoma patients. 15 The development of treatments tailored to enhance the efficacy of bortezomib without increasing its secondary toxicity has been complicated by a lack of consensus on the impact of proteasome inhibition on the apoptotic cascade in tumor cells. In particularly, the impact of bortezomib on Bcl-2 family members is unclear. Depending on the cell type, Bcl-2, Bcl-x L and Bax can be either unaffected by bortezomib, downregulated before the activation of the apoptotic machinery, or inhibited after caspases are processed. 9, 16 Mcl-1 levels accumulate in response to bortezomib, [6] [7] [8] but Mcl-1 is also cleaved by caspases once apoptosis is induced. 6, 17 Interestingly, partial downregulation of Mcl-1 was shown to cause a twofold increase in bortezomib-mediated melanoma killing in culture. 7 The question of how to efficiently block Mcl-1 and improve the antitumoral activity of bortezomib in vivo remains.
Small molecule inhibitors of antiapoptotic Bcl-2 proteins are emerging as potent tools to address functional components of the apoptotic machinery, with the ultimate objective of overcoming tumor chemoresistance. 18, 19 Intense effort has been dedicated to the development of compounds that mimic the Bcl-2 homology domain 3 (BH3) domain of pro-death Bcl-2 proteins. 18, 20 ABT-737, the best characterized BH3 mimetic to date, synergizes with compounds such as dexamethasone or paclitaxel. 21 Unfortunately, ABT-737 had a relatively modest effect on the cytotoxicity of bortezomib (1.3-fold induction of cell death). 22 A likely explanation for this limited cooperation is that ABT-737 has a high affinity for Bcl-2 and Bcl-x L , but binds poorly to Mcl-1, 21 which is induced by bortezomib. Broader spectrum antagonists of antiapoptotic Bcl-2 proteins are being investigated (reviewed by Zhai et al. 20 ). These include the natural products or derivatives of epigallocatechin gallate (EGCG), gossypol, antimycin A and chelerythrine; as well as synthetic compounds GX-15, BH3I-1, TW-37 and YC-137. Among these, the lowest IC 50 values for Mcl-1 have been reported for EGCG and gossypol (0.92 and 1.75 mM, respectively). Gossypol is interesting because, to our knowledge, it is the only bioavailable compound able to bind Mcl-1 23 that is in being tested in phase II clinical trials. 24 In the context of melanoma, gossypol has long been known to kill melanoma cells more efficaciously than normal melanocytes. [25] [26] [27] However, the mechanism(s) underlying this selectivity is unclear.
Here, we report a comparative analysis of cell survival mechanisms in melanoma cells and normal melanocytes with blocked proteasomal function. We combine genetic and pharmacological approaches (based on RNA interference and gossypol, respectively) to address the impact of specific Bcl-2 family members in response to bortezomib in vitro and in vivo. We show that the regulation and functional requirement of Bcl-2, Bcl-x L and Mcl-1 are not equivalent in melanoma cells versus normal melanocytes. Moreover, melanoma cells, but not melanocytes, require Mcl-1 and Bcl-x L for survival when the proteasome is blocked. This study provides new insight into the relationship between the proteasome and the apoptotic machinery in melanoma, which could be exploited to design more effective and selective therapies.
Results
Identification of protective signals opposing bortezomib killing of melanoma cells. To address mechanisms of melanoma resistance to bortezomib, SK-Mel-19, SK-Mel-103 and SK-Mel-147 were chosen as representative melanoma cell lines that respond to bortezomib by undergoing programmed cell death. 5, 6 Consistent with previous reports, 5, 6 bortezomib induced NOXA efficiently in all three lines, but was not rapidly cytotoxic (Figure 1a -c). Cells were collected at different time points following bortezomib treatment, and the expression of NOXA, Mcl-1, Bcl-x L and Bcl-2 visualized by immunoblotting. Processing of regulatory caspases (casp-9 and -8) and effector caspases (casp-3 and -7) was monitored as a classical indicator of apoptosis activation.
As shown in Figure 1a Figure 1d -f). Note that significant cell death was not achieved until regulatory and effector caspase cleavage was detected and Mcl-1 expression was reduced to or below basal levels (Figure 1d-f) . Bcl-2 and Bcl-x L expression remained high during treatment, and did not change upon caspase cleavage. These results emphasize the differential regulation of Bcl-2 family members by the proteasome, supporting the notion that the idiosyncratic rate of synthesis and accumulation of Mcl-1 may serve as an internal brake opposing the toxicity of proteasomal inhibition. 7 Multitarget BH3 mimetics to improve the efficacy of bortezomib. Given the massive induction of Mcl-1 by bortezomib, and the sustained levels of Bcl-2 and Bcl-x L , after treatment, blocking these three antiapoptotic proteins may improve the efficacy of proteasome inhibition in vivo. To test this possibility, we focused on gossypol, a bioavailable compound with BH3 functions, which had a safe profile in clinical trials. 23 Natural gossypol (a mixture of (À) and ( þ ) enantiomers) binds Mcl-1, Bcl-2 and Bcl-x L with IC 50 values of 1.74, 0.28 and 3.03 mM, respectively. 20 However, a number of reports have shown that of the two enantiomers, (À)-gossypol is significantly the most potent anticancer agent in vitro and in vivo. 23 To estimate the binding affinities of (À)-gossypol for individual Bcl-2 family members, competition fluorescence polarization assays were performed with a fluorescently tagged Bid BH3 peptide. 24 K i values were determined instead of binding concentrations, as they more directly measure the inhibitory capacity of (À)-gossypol. As shown in Figure 2a , the K i values of (À)-gossypol for Mcl-1, Bcl-2 and Bcl-x L were 180, 320 and 480 nM, respectively. Because of its high affinity for Mcl-1, we utilized the (À) enantiomer of gossypol in our studies of melanoma resistance to bortezomib.
When combined with bortezomib in vitro, (À)-gossypol selectively enhanced melanoma cell death. As shown in Figure 2b , the addition of (À)-gossypol increased cell killing in each of the melanoma lines tested, without affecting the viability of normal melanocytes (Figure 2b , see also Figure 2c for representative microphotographs). These data suggest a tumor-restricted cooperativity between (À)-gossypol and proteasome inhibition.
Antitumor effect of the (À)-gossypol/bortezomib combination in vivo. We have previously shown that, among a panel of 19 melanoma lines, the SK-Mel-103 and SK-Mel-147 lines grow most aggressively in immunosuppressed mice. 6 Therefore, these two cell lines were selected for treatment assays in vivo.
To started to proliferate actively (48 h after the s.c. implantations and 72 h after the i.v. injections). 6 Bortezomib and (À)-gossypol were administered systemically at concentrations below their described maximum tolerated dose (see Materials and methods).
Bortezomib was able to reduce growth of the SK-Mel-103 s.c. xenografts (see representative examples in Figure 3a and quantification in Figure 3b ). However, as previously described, 6 this effect was not statistically significant (P ¼ 0.190). Tumor growth was also delayed by (À)-gossypol (P ¼ 0.043). However, the combination of (À)-gossypol and bortezomib was significantly more potent than each agent alone (P ¼ 0.005; Figure 3a and b).
While these results are encouraging, the impact of the drug combinations on the control of metastatic dissemination is perhaps more relevant, since metastasis is the leading cause of death in melanoma patients. [1] [2] [3] The (À)-gossypol/bortezomib combination provided a significant reduction in metastatic growth of SK-Mel-103 and SK-Mel-147 (Figure 3c and d) . Consequently, the antitumor effect of bortezomib/(À)-gossypol improved overall survival. By day 17 of treatment, more than 70% of control mice had either died or were moribund as result of significant respiratory complications. In contrast, no deaths occurred in the (À)-gossypol/bortezomib combination group, and these mice showed no signs of discomfort. Macroscopic analyses of lungs implanted with cell line SK-Mel-147 revealed a reduced size and number of metastatic nodules after treatment with both drugs (Figure 3c Genetic analysis of the contribution of antiapoptotic Bcl-2 proteins to tumor cell survival after proteasomal inhibition: RNA interference A variety of biochemical and mechanistic analyses in multiple cancer types have demonstrated the antitumoral activity of (À)-gossypol, primarily linked to its role as a BH3 mimetic.
However, dysregulation of mitochondrial and redox-dependent functions by gossypol can affect, directly or indirectly, other cellular processes 23 that may act in a BAX/BAK independent manner. 28, 29 Therefore, a genetic approach utilizing RNA interference was developed to validate the BH3-dependent function of (À)-gossypol, and to establish the hierarchical requirement of various Bcl-2 family members for viability upon bortezomib treatment. Specifically, short hairpins against unique regions of Mcl-1, Bcl-x L or Bcl-2 were cloned into an eGFP-expressing lentiviral vector to generate short hairpin RNAs (shRNAs) (Figure 4a Differential impact of Mcl-1, Bcl-x L and Bcl-2 on the resistance of melanoma cells to bortezomib. Long-term downregulation of either Bcl-2 or Bcl-x L can induce cell death in melanocytes. 31, 32 However, temporal inactivation of these genes by the shRNAs indicated above (mimicking acute treatments typical of clinical trials) was well tolerated by both melanocytes and melanoma cells (Figure 4b ). Mcl-1 shRNA was also non-toxic for melanocytes (Figure 4b) . Therefore, isogenic series of normal melanocytes, and of SK-Mel-19, SK-Mel-103 and SK-Mel-147 (generated by specific inactivation of Mcl-1, Bcl-x L or Bcl-2), were used to assess the hierarchical contributions of Bcl-2 family members to bortezomib resistance. The different populations were treated with sublethal doses of bortezomib, and cell death was determined by trypan blue exclusion at various time points. The reduction of Mcl-1 levels was shown to have a dramatic impact on the kinetics and final extent of bortezomib-induced cell death (Figure 5a ). For example, while more than 50 h were required to kill 70% of the parental SK-Mel-19 cell line (Figure 1a) , a similar extent of cell death could be achieved by 18 h when Mcl-1 was downregulated (Figure 5a ). Even in cells from lines SK-Mel-103 or SK-Mel-147, which are intrinsically sensitive to bortezomib, Mcl-1 downregulation had a significant effect (i.e. death rates observed by 18 h in Mcl-1-expressing cells could be achieved as early as 6 h when Mcl-1 was downregulated; Figure 5a ). Analysis of cytochrome c (Cyt c) release from the mitochondria confirms the acceleration of apoptosis (Figure 5b ). Considering the potent antiapoptotic effect of Bcl-2 in response to standard chemotherapeutic agents, 33 its downregulation was surprisingly ineffective in favoring bortezomib-induced cell death. Neither SK-Mel-19, SK-Mel-103 nor SK-Mel-147 showed an altered response to bortezomib when Bcl-2 was downregulated by shRNA (Figure 5a ). Bcl-x L downregulation, however, caused a noticeable acceleration of the killing by bortezomib in all three lines (Figure 5a ; see Supplementary Figure 1 for visualization of cell detachment). Therefore, these results indicate that, in addition to Mcl-1, Bcl-x L , should be considered as a target to improve the efficacy of bortezomib.
The roles of Mcl-1, Bcl-x L and Bcl-2 in cell survival upon proteasome inhibition were also studied in normal melanocytes. In these cells, any of these three proteins could be downregulated (Figure 4c Figure 3) .
In addition to NOXA, Mcl-1 can bind other proteins in the Bcl-2 family. Currently, there is an active debate regarding how pro-and antiapoptotic proteins of this family are interregulated to control mitochondrial-dependent death programs. 34, 35 To assess the specific contribution of NOXA to the increased response to bortezomib following Mcl-1 downregulation, we again exploited RNA interference. We infected melanoma cells with a lentivirus coding for a highly efficient shRNA against NOXA, 6 which is able to abrogate even the massive accumulation of this protein upon proteasome inhibition (see examples in Figure 6b ). As shown in Figure 6c , blockade of NOXA in SK-Mel-19 compromised the stimulatory effect of Mcl-1 downregulation, reducing the amount of cell death to levels below the parental controls. These effects were found across a range of bortezomib dosages and different treatment times (Figure 6b , and results not shown). Altogether, shRNA interference affords novel insights into the activation of the intrinsic apoptotic machinery in melanoma cells, which are impervious to standard chemotherapeutic agents.
Discussion
In this study, we utilized genetic and pharmacological approaches to identify intrinsic mechanisms of resistance to ment for Mcl-1 and, to a lesser extent, for Bcl-x L in resisting bortezomib. However, both of these proteins are largely dispensable to normal melanocytes after bortezomib treatment, offering a window for therapeutic intervention.
From a translational point of view, compounds able to minimize the time delay from proteasomal inhibition to the activation of the apoptotic machinery in a tumor cell-selective manner could have important implications. In clinical practice, to limit secondary toxicity, proteasome inhibition by bortezomib is neither complete nor sustained. 9 Bortezomib is typically administered by bolus injection, leaving residual proteasomal activity of 20-30% and allowing for recovery between treatment cycles. Moreover, pharmacokinetic analyses indicate that bortezomib is rapidly inactivated by hepatic detoxification. 36 Therefore, there is interest in compounds that can act in a synergistic manner with bortezomib without compromising the viability of normal cells. This need is particularly important in metastatic melanoma patients, whose average survival of 6-10 months could not be improved with the current dosing and administration route of bortezomib. 15 The rational design of new treatments to overcome bortezomib resistance in melanoma cells is complicated by several hurdles. First, the ubiquitin/proteasome system controls the half-life of nearly 80% of cellular proteins, both in normal and tumor cells, and no consistent predictive markers of response to bortezomib have been identified in vivo. 9 Furthermore, potent proapoptotic factors such as Bim EL can be induced by proteasome inhibition in melanocytes as efficiently as in their tumor counterparts 5 ( Figure 7 ). Therefore, normal cell compartments may be inherently 'at risk' of stress driven by proteasome inhibition, and thus rely on mechanisms of protection to maintain their viability.
An additional barrier to drug development in melanoma is a complex genetic background with defects in all known survival pathways capable of blocking apoptosis upstream and downstream of the mitochondria. In particular, Bcl-2, Bcl-x L and Mcl-1 can play key roles in controlling both caspasedependent and independent pathways in response to a variety of chemotherapeutic agents. The functional hierarchy of these antiapoptotic factors, and their ultimate mechanism of action in the control of melanoma cell maintenance, is unclear. The interplay between pro-and antiapoptotic members of this family is under debate in multiple systems (reviewed by Green 34 and Youle 35 ). According to the so-called 'displacement model', Mcl-1, Bcl-2 and Bcl-x L directly inhibit proapoptotic BAX and/or BAK. 37 In this case, competitive BH3 mimetics, or strategies to efficiently block Mcl-1/Bcl-2/Bcl-x L function, are sufficient to engage mitochondrial dysfunction.
Figure 7
Differential regulation and requirement of Bcl-2 family members in melanoma cells and melanocytes treated with bortezomib. Bcl-2 family members can be grouped in three categories depending on their regulation by the proteasome: (i) Proteasome independent (e.g. Bcl-2, Bcl-x L , BAX, BAK; here depicted in black); (ii) regulated by the proteasome in a tumor cell-specific manner (NOXA; shown in red); and (iii) controlled by the proteasome in normal and tumor cells (e.g. Mcl-1 and Bim EL ; shown in blue). Surprisingly, despite the significant induction of Bim EL in melanocytes, these cells are largely independent of Mcl-1, Bcl-x L or Bcl-2 for survival. Melanoma cells, however, significantly die if Mcl-1 is removed. A noticeable acceleration of cell death is also found by blocking Bcl-x L . However, Bcl-2 was dispensable for the viability of bortezomibtreatment melanoma cells. These results emphasize the non-equivalent functional requirement of Bcl-2 family members in normal melanocytes and melanoma cells that can be exploited for rational drug design Conversely, the 'direct binding model' argues that removal of antiapoptotic proteins is insufficient, per se, to promote cell death, and that additional proapoptotic inducers are required for full activation of BAX and BAK. 14, 38, 39 Our shRNA data are consistent with this second scenario. Thus, melanoma cells can tolerate an acute downregulation of Mcl-1, Bcl-x L or Bcl-2. Bortezomib can provide the additional death signal needed, by potent, tumor-selective induction of NOXA (see model in Figure 7 ).
Since NOXA preferentially binds to and is countered by Mcl-1 13, 14 it is not surprising that Mcl-1 shRNA dramatically accelerated bortezomib killing of melanoma cells. However, the fact that Mcl-1 is dispensable for the viability of melanocytes was unexpected, considering that Mcl-1 is a main blocker of Bim EL , which is highly induced in melanocytes upon bortezomib treatment (Figure 7) . In this context, it is also intriguing that neither Bcl-2 nor Bcl-x L downregulation compromise the viability of bortezomib-treated melanocytes.
Our data showing a hierarchical organization of apoptotic modulators in the response of melanoma cells to bortezomib (i.e. Mcl-14Bcl-x L bBcl-2) have implications for future drug design. Inactivation of Bcl-2 or Bcl-x L alone may not be sufficient to counteract resistance to proteasome inhibitors. In this context, our results provide a molecular explanation for the only modest enhancement of bortezomib-induced cell death with the BH3 mimetics, ABT-737 22 and BH3I-2 0 , 40 which bind poorly to Mcl-1. Conversely, (À)-gossypol and other BH3 mimetics with high affinity for Mcl-1 and Bcl-x L can dismantle the protective shield that halts caspase activation in melanoma cells. The significant activity of the (À)-gossypol/bortezomib combination in blocking melanoma growth in the metastatic dissemination model is encouraging, considering that these cells are invariably resistant to standard anticancer agents. Second generation BH3 mimetics based on gossypol are being generated with the objective of improving binding to Mcl-1. 23 These new reagents may ultimately provide a longterm response in combination with bortezomib.
In summary, this study has addressed the interplay between the proteasome and key modulators of the apoptotic machinery in melanoma. Our results identify members of Bcl-2 family with differential regulation by the proteasome, and a differing requirement for the survival of melanocytes versus melanoma cells. We provided evidence, both in vitro and in vivo, for the design of rational combination strategies utilizing BH3 mimetics with high affinity for Mcl-1 and Bcl-x L to improve the efficacy of proteasome inhibition. Such agents could represent a new strategy to overcome the traditional chemoresistance of malignant melanoma.
Materials and Methods Cells. The metastatic melanoma cell lines SK-Mel-19, SK-Mel-29, SK-Mel-103 and SK-Mel-147 were obtained from the Memorial Sloan-Kettering Cancer Center, NY, USA. These cells were cultured in Dulbecco's modified Eagles's medium (Life Technologies, Rockville, MD, USA) supplemented with 10% fetal bovine serum (Nova-Tech Inc., Grand Island, NY, USA). Human melanocytes were isolated from human neonatal foreskins as described 6 and maintained in Medium 254 supplemented with melanocyte growth factors (HMG-1) containing 10 ng/ml phorbol 12-myristate 13-acetate (Cascade Biologics, Portland, OR, USA).
Reagents. Bortezomib (Velcadet; formerly PS-341) was obtained from Millennium Pharmaceuticals (Cambridge, MA, USA). For analyses in tissue culture systems, bortezomib was reconstituted in DMSO at a concentration of 0.1 mM, and for studies in vivo it was prepared in a 0.85% sterile saline solution at a concentration of 1.2 mg/ml. (À)-Gossypol was synthesized as described previously. 24 For oral dosing, lyophilized (À)-gossypol was resuspended in 100% ethanol, and subsequently diluted in sterile water to 10% ethanol, for a working concentration of 1.5 mg/ml.
Fluorescence polarization assays. Inhibitory binding constants of (À)-gossypol to purified Bcl-2, Bcl-x L and Mcl-1 were determined by competitive fluorescence-polarization-based binding assays as described. 30 In short, a Bid BH3-containing peptide (residues 79-99) was labeled at the N-terminus with 6-carboxyfluorescein succinimidyl ester (FAM). A 1-2.5 nM portion of FAM-Bid peptide was preincubated with purified Bcl-2 (40 nM) or Mcl-1 (5 nM) in 100 mM potassium phosphate pH 7.5; 100 mg/ml bovine gamma globulin; 0.02% sodium azide. To determine the K i values for Bcl-x L , fluorescence polarization assays were performed with 30 nM Bcl-x L in 50 mM Tris-Bis, pH 7.4 and 0.01% bovine gamma globulin. Polarization values were measured using a Ultra plate reader (Tecan US Inc., Research Triangle Park, NC, USA) in the absence or in the presence of increasing concentrations of (À)-gossypol. Excitation and emission wavelengths were set at 485 and 530 nm, respectively. Purified protein or fluorescent probes were also included as reference controls. K i values were calculated with GraphPad Prizm 4 software (GraphPad Software, San Diego, CA, USA) using previously described equations (http://sw16.im.med.umich.edu/software/calc_ki/). 24 Protein immunoblotting. To determine changes in protein levels, 2 Â 10 6 cells were treated with bortezomib (50 nM) and harvested at the indicated time points after treatment. Total cell lysates were subjected to electrophoresis in 12, 15 or 4-15% gradient SDS gels under reducing conditions, and subsequently transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Protein bands were detected by the ECL system (GE Healthcare, Buckinghamshire, UK). Primary antibodies included: casp-9 and -3 from Novus Biologicals (Littleton, CO, USA); casp-8 (Ab-3) from Oncogene Research Products (San Diego, CA, USA); casp-7 from Cell Signaling Technology (Beverly, MA, USA); Bcl-x L from BD Transduction Laboratories (Franklin Lakes, NJ, USA); Bcl-2 from Dako Diagnostics (Glostrup, Denmark); NOXA from Calbiochem (San Diego, CA, USA); and tubulin (clone AC-74) from Sigma Chemical (St Louis, MO, USA). Secondary antibodies were either anti-mouse or anti-rabbit from GE Healthcare. Image J was used to quantify changes in protein levels induced by bortezomib, considering untreated controls as reference for basal expression. Caspase processing was analyzed by immunoblotting with specific antibodies. Changes in the inactive/cleaved forms of specific caspases were quantified using Image J software and plotted as a function of time.
Cell death assays/Cyt c visualization. The percentage of cell death at the indicated times and drug concentrations was estimated by standard trypan blue exclusion assays. Briefly, floating and adherent cells were pooled, stained with a 0.4% trypan blue solution (Gibco Laboratories, Grand Island, NY, USA) and scored under a light microscope (a minimum of 500 cells per treatment were counted). Cyt c localization was visualized by immunofluorescence in cells fixed with 4% formaldehyde essentially as described previously. 30 Where indicated, nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) using standard methods.
RNA interference. Lentiviral vectors used to downregulate Bcl-2, Bcl-x L , Mcl-1 and NOXA have been previously reported. 6, 30 In summary, the sequences used to generate short hairpin interfering RNAs were as follows. Bcl-2 (1): nt. 197-215; Bcl-2 (2): nt. 500-518; Bcl-x L : nt. 714-732; Mcl-1: nt. 2343-2362; and NOXA: nt. 1177-1195. Unspecific oligonucleotides were also designed to generate control shRNA. Viruses were generated from 293FT cells and titers were used to provide 480% infection efficiency. The efficacy and specificity of each construct was determined by protein immunoblotting (see text). When indicated, treatment with bortezomib was initiated 3 days after infection with the corresponding shRNA-expressing viruses.
Analysis of drug response in animal models (mouse xenografts). GFP-expressing melanoma cells were injected i.v. into the mouse tail vein (n ¼ 10). Treatment was initiated 48 or 72 h after the s.c. or i.v. tumor implantations, respectively. Animals were weighed every 2 days to ensure maintenance of total weight within 80% of control populations. Bortezomib was administered systemically by intraperitoneal injection (1.0-1.3 mg/kg) in a rotating 2-day schedule. 6 Similar results were obtained for treatments performed via i.v. administration (data not shown). (À)-Gossypol was administered orally at a daily dose of 15-20 mg/kg. Imaging of tumor cells in vivo was performed with an Illumatool TLS LT-9500 fluorescence light system (Lightools Research, Encinitas, CA, USA) and the emitted fluorescence from tumor cells was captured with a Hamamatsu Orca 100 CCD camera. Volumes of the s.c. xenografts were estimated as V ¼ LW 2 /2, where L and W stand for tumor length and width, respectively. Pathological analyses of internal organs were guided by fluorescence imaging. Lungs and lymph nodes were harvested and weighed, and external metastases were counted manually and scored by number and size. Metastatic involvement was monitored independently by analysis of hematoxylin-eosin staining of paraffin sections. Mice were euthanized when control populations showed signs of discomfort or respiratory defects.
Statistical analyses. Statistical evaluation of tumor growth and metastasis in vivo was performed using the Statistical Package of the Social Sciences (SPSS) version 11.5 for Windows. Non-parametric Kruskal-Wallis H-test was used for X-group comparisons and Mann-Whitney U-test for two-group comparisons. Two-tailed P-values smaller than 0.05 were considered statistically significant.
